Sns-595 and methods of using the same

Abstract

The present invention relates to SNS-595 and of treating cancer using the same.

1 . A method for treating ovarian cancer comprising administering to a patient having ovarian cancer a dose of 10 mg/m 2 -150 mg/m 2  of (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid. 
     
     
         2 . The method of  claim 1  wherein the dose is 10 mg/m 2 -100 mg/m 2 . 
     
     
         3 . The method of  claim 1  wherein the dose 30 mg/m 2 -75 mg/m 2 . 
     
     
         4 . The method of  claim 1  wherein the dose is 40 mg/m 2 -80 mg/m 2 . 
     
     
         5 . The method of  claim 1  wherein the dose is 50 mg/m 2 -90 mg/m 2 . 
     
     
         6 - 8 . (canceled) 
     
     
         9 . The method of  claim 1  additionally comprising administering to said patient a therapeutically effective dose of a supportive care agent. 
     
     
         10 . The method of  claim 9  wherein the supportive care agent is an antiemetic. 
     
     
         11 . (canceled) 
     
     
         12 . A method for treating ovarian cancer comprising: i) administering a dose of 10 mg/m 2 -150 mg/m 2  of (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid to a patient having ovarian cancer; ii) waiting a period of at least one day where the patient is not administered any (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid; iii) administering another dose of 10 mg/m 2 -150 mg/m 2  of (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid to the patient; 
     
     
         13 . The method of  claim 12  wherein the period is at least 2 days. 
     
     
         14 . The method of  claim 12  wherein the period is at least 3 days. 
     
     
         15 . The method of  claim 12  wherein the period is at least 6 days. 
     
     
         16 . The method of  claim 12  wherein the period is at least 13 days. 
     
     
         17 . The method of  claim 10  wherein the period is at least 20 days. 
     
     
         18 . The method of  claim 10  wherein the period is at least 27 days. 
     
     
         19 . A method for treating ovarian cancer comprising administering a weekly dose of 10 mg/m 2 -150 mg/m 2  of (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid to a patient having ovarian cancer. 
     
     
         20 . A method for treating ovarian cancer comprising administering a dose of 10 mg/m 2 -150 mg/m 2  of (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid once every three weeks to a patient having ovarian cancer. 
     
     
         21 . A method for treating ovarian cancer comprising a cycle wherein the cycle comprises administering a dose of 50 mg/m 2 -110 mg/m 2  of (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid to a subject having ovarian cancer once every week for three weeks followed by a period of at least two weeks where no (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid is administered to said subject and wherein the cycle is repeated a plurality of times. 
     
     
         22 - 26 . (canceled)